Menu
Search
|

Menu

Close
X

SAGE Therapeutics Inc SAGE.OQ (NASDAQ Stock Exchange Global Market)

114.21 USD
+2.33 (+2.08%)
As of Nov 16
chart
Previous Close 111.88
Open 111.83
Volume 137,345
3m Avg Volume 133,124
Today’s High 115.27
Today’s Low 111.00
52 Week High 195.97
52 Week Low 83.56
Shares Outstanding (mil) 46.89
Market Capitalization (mil) 5,112.11
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.69 Mean rating from 16 analysts

KEY STATS

Revenue (mm, USD)
FY18
90
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-4.679
FY17
-7.090
FY16
-4.693
FY15
-3.383
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
56.80
20.58
Price to Book (MRQ)
vs sector
5.17
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
0.00
13.84
LT Debt to Equity (MRQ)
vs sector
0.00
9.93
Return on Investment (TTM)
vs sector
-47.57
13.58
Return on Equity (TTM)
vs sector
-47.77
15.11

EXECUTIVE LEADERSHIP

Kevin Starr
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Jeffrey Jonas
President, Chief Executive Officer, Director, Since 2013
Salary: $600,000.00
Bonus: --
Kimi Iguchi
Chief Financial Officer, Treasurer, Since 2016
Salary: $356,928.00
Bonus: --
Anne Cook
Senior Vice President, General Counsel, Secretary, Since 2017
Salary: $376,423.00
Bonus: --
Albert Robichaud
Chief Scientific Officer, Since 2011
Salary: $365,699.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

215 1st St
CAMBRIDGE   MA   02142-1213

Phone: +1617.2998380

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

SPONSORED STORIES